Gwenny M Verstappen,Zana Brkic
Gwenny M Verstappen
Interferon-α as a precision medicine tool in Sjögren's disease: a cohort and experimental medicine study [0.03%]
干扰素α作为类风湿性关节炎的精准医疗工具：队列和实验医学研究
Deborah Forbes,Ivana Jorgacevic,Jessica Tarn et al.
Deborah Forbes et al.
Background: Mechanistic heterogeneity is a major obstacle to the development of effective treatment for Sjögren's disease, and there is a pressing need to stratify Sjögren's disease according to precision medicine princ...
Long-term durability of a time-limited methotrexate intervention in patients with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative arthralgia at increased risk for rheumatoid arthritis (TREAT EARLIER): 5-year data from a double-blind, randomised, placebo-controlled trial [0.03%]
针对类风湿关节炎高危抗瓜氨酸蛋白抗体阳性和阴性关节痛患者的甲氨蝶呤限时干预长期疗效：EARLIER试验5年数据报告一项双盲随机安慰剂对照试验
Elise van Mulligen,Quirine A Dumoulin,Hanna W van Steenbergen et al.
Elise van Mulligen et al.
Background: The TREAT EARLIER trial showed that a time-limited intervention with 12 months of methotrexate in individuals with arthralgia at risk of rheumatoid arthritis improved inflammatory burden but did not prevent rh...
Lihi Eder,Alexis Ogdie
Lihi Eder
Jeffrey A Sparks
Jeffrey A Sparks
Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study [0.03%]
基于初始队列研究的新发银屑病患者发生银屑病关节炎的预测模型研究
Axel Svedbom,Lotus Mallbris,Alen Zabotti et al.
Axel Svedbom et al.
Background: Psoriatic arthritis is underdiagnosed in people with psoriasis. Delayed psoriatic arthritis diagnosis is associated with worse outcomes, whereas early intervention improves prognosis. Therefore, we aimed to de...
Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY [0.03%]
英国开放安全计划（OpenSAFELY）在新冠疫情前后对自身免疫性风湿病诊断趋势的队列研究
Mark D Russell,Andrea Schaffer,Zijing Yang et al.
Mark D Russell et al.
Background: During the first year of the COVID-19 pandemic, diagnosis rates were reported to have declined for several autoimmune rheumatic diseases in numerous countries. It remains unclear whether diagnosis rates have s...
Marc Scherlinger,Laurent Chiche
Marc Scherlinger
Secukinumab biosimilar BAT2306 versus reference secukinumab in patients with moderate-to-severe plaque psoriasis: a multicentre, double-blind, randomised, active-controlled, phase 3 trial [0.03%]
贝伐单抗类似药BAT2306治疗中重度斑块状银屑病的多中心、双盲、随机、阳性对照三期临床试验
Jia-Qi Chen,Rongyi Chen,Liming Wu et al.
Jia-Qi Chen et al.
Background: Secukinumab is licensed for the treatment of moderate-to-severe plaque psoriasis in adults. BAT2306 is a proposed biosimilar to reference secukinumab. We aimed to compare the safety, efficacy, pharmacokinetics...
Low-dose and very low-dose glucocorticoids: which low is low risk? - Authors' reply [0.03%]
低剂量和非常低剂量糖皮质激素：哪种剂量风险低？——作者回复
Frank Buttgereit,Lai-Shan Tam
Frank Buttgereit